Ten decisions to close before v3.2 freezes.
Purpose of this meeting
This is not a status share. This is a decision meeting.
Ten items below need a founder-team answer before the next artifact pass (v3.2) freezes and before SAFE readiness moves from checklist to critical path. For each item:
- Recommendation — Brandon's current answer.
- Rationale — why, in one line.
- Action for the meeting — ratify, amend, or defer with a named next step.
Section A · Seven Ledger §7 items (must close)
Longview / Thrive Forward / Ayupaya / new
Recommendation Defer to a dedicated brand-naming session inside 14 days; use "HIFP" as placeholder in all v3.2 artifacts.
Rationale No option in the current shortlist is unanimously loved; naming under time pressure produces a name we regret. Better to run a proper session with a shortlist of 6–8 including agency-generated candidates.
Action Book the brand session before end of meeting.
CMO / COO / Chief Clinical Officer / President
Recommendation Chief Clinical Officer.
Rationale Sindhu's stated passion is user agency + actionable value in health/wealth decisions (Session 2026-09-03). CCO anchors the clinical-authority credential that carries the Advice-Boundary work + the physician-community relationships. CMO reads as marketing; COO reads as operations; President is premature. CCO is the load-bearing title.
Action Sindhu ratifies or names an alternative; if the alternative is anything but CCO, name the reason so the Change Log can carry it.
AWS declared in POV v3.1 r2
Recommendation AWS confirmed. Cloudflare edge (CDN + WAF); frontend on AWS Amplify or Vercel per founding-engineer preference.
Rationale HIPAA BAA, chain-partner inspectability, and the founding-engineer market all point AWS. GCP and Azure both viable but neither wins on all three axes.
Action Fatima + Sindhu ratify or flag concern.
Recommendation Defer to post-SAFE. Vendor is a downstream selection; specific decision belongs to the Medical Lead advisor + Sindhu + counsel once retainer is funded.
Rationale Selecting today locks vendor economics before the Advice-Boundary corpus specification is complete. Premature.
Action Confirm defer; add to post-SAFE §5 vendor list.
CPO/CTO combined through Series A → CPO after VP Eng hire
Recommendation Ratify (Brandon-confirmed; needs Fatima + Sindhu sign-off).
Rationale Removes $500–800K Y1 cost; leans on Brandon's dual-architect credential; VP Eng in Y2 covers scale risk.
Action Verbal ratification; captured in meeting notes.
MVP tile stub + H1 full functionality
Recommendation Ratify. MVP ships view-only invite affordance under Settings → Household. H1 unlocks the multi-user permission model + sandwich-generation surface + household pricing.
Rationale Sandwich-generation has emerged as the highest-signal product insight from the POC. H1 activation preserves MVP scope discipline without losing the story.
Action Ratify or push a decision to lift Household into MVP proper (would add ~4–6 eng-wk to MVP).
Health/longevity-strategic vs. AI-forward generalist
Recommendation Lead health/longevity-strategic; keep AI-forward generalist as parallel warm-lane.
Rationale Health-lane investors close faster on this thesis and bring domain credibility to the round. AI-lane investors are additive but the deck has to translate; leading with AI positions HIFP as an AI-application play, which under-sells the actuarial + clinical + trust moat.
Action Ratify sequencing or flip.
Section B · Three items from the Sindhu 2026-09-03 session
Strategic reframe
Recommendation Adopt Sindhu's framing as a v3.2 thesis-level update. Reshape Plan-Delta hierarchy, advisor share view, and pitch narrative so the wealth-action surface is the "so what" and the health signal is the "why now."
Rationale Sharpens the value prop meaningfully. "Biomarkers move the plan" becomes "biomarkers move the wealth plan" — actionable, advisor-legible, HNW-resonant.
Action Founder-team acknowledgment; Brandon writes into POV v3.2 §3.2 reframe.
Fin-services marketplace (Envestnet-adjacent, product-referral) Recommendation: remain pivoted-away. Collides with advice-boundary + restraint-brand + share-with-incumbent. Land the "no" on the Pivot Log with reasoning.
Data-source partnership marketplace (Oura / Galleri / HLI / aggregators) Recommendation: open track. Clean of advice-boundary. Sixth commercial-lever candidate if partner-paid; CAC-reduction lever if HIFP-paid. Brandon scopes structure options in v3.2.
Action Founder-team acknowledgment on both directions.
Recommendation Re-pivot away — but explicitly this time. Reasoning: demographic dissonance with HNW 45–70 target + chain-channel signal mismatch. Land the "no" on the Pivot Log so it does not get re-asked at v4.
Action Founder-team acknowledgment.
Section C · One meta-decision
Recommendation Ship v3.2, not v4. Reserve v4 for post-SAFE-close, post-first-chain-signed, or post-first-k-factor-read. v3.2 absorbs Sindhu-session insights + POC additions + Change Log + role/title corrections. Substantial but scoped.
Action Ratify.
Meeting output expected
By the end of the meeting, this document is annotated with:
- Ratified / amended / deferred stamp on each of A1–A7, B1–B3, C1.
- Brand-naming session on the calendar (A1).
- Sindhu's final title (A2).
- Fatima's + Sindhu's ratification on A5 + A6.
- Investor-lane sequencing (A7).